Magnesium Oxide Interaction with Mycophenolate
Yes, magnesium oxide significantly interacts with mycophenolate mofetil by reducing its absorption, and these medications should not be administered simultaneously.
The Interaction Mechanism
Magnesium-containing antacids (including magnesium oxide) decrease mycophenolate absorption through direct binding in the gastrointestinal tract. The FDA drug label explicitly states that when mycophenolate mofetil was coadministered with magnesium and aluminum hydroxide-containing antacids, the Cmax decreased by 33% and AUC decreased by 17% 1. This represents a clinically meaningful reduction in drug exposure that could compromise immunosuppression efficacy.
Clinical Management Strategy
Separate the administration times if both medications are necessary:
- Mycophenolate mofetil may be administered to patients taking magnesium-containing antacids
- However, do not give them simultaneously 1
- Space the doses by at least 2-3 hours to minimize the interaction
The FDA labeling is clear: "it is recommended that mycophenolate mofetil and the antacid not be administered simultaneously" 1.
Supporting Evidence
Multiple authoritative sources confirm this interaction:
- American Journal of Transplantation guidelines (2001) note that "the bioavailability of mycophenolic acid, the active metabolite of mycophenolate mofetil, may be reduced by aluminum/magnesium hydroxide containing antacids" 2
- CHEST guidelines (2012) specify that "aluminum or magnesium salts can inhibit absorption from the GI tract" 3
- Research studies demonstrate approximately 15-17% reduction in MPA exposure with antacid coadministration 4, 5
Critical Considerations
While the magnitude of this interaction (15-37% reduction depending on the parameter measured) may seem modest compared to interpatient variability 5, in transplant patients, any reduction in immunosuppressive drug exposure increases rejection risk. The stakes are too high to dismiss this interaction as clinically insignificant.
Do not use alternative strategies like cholestyramine or other bile acid sequestrants, as these cause even more severe reductions (approximately 40% decrease in MPA AUC) 1.
If gastrointestinal symptoms require treatment, consider non-magnesium alternatives or ensure strict dose separation to maintain adequate immunosuppression.